Rocket Pharmaceuticals, Inc. filings document regulatory, financial, governance, and capital-structure disclosures for a biotechnology company developing and commercializing genetic therapies for rare disorders. Recent 8-K reports cover quarterly and annual operating results, FDA-related events for KRESLADI, Priority Review Voucher monetization, and clinical-program updates for cardiovascular gene therapy candidates.
The filing record also includes definitive proxy materials for annual-meeting governance matters and material-agreement disclosures related to an at-the-market common stock offering program under a shelf registration statement. These documents describe board and shareholder-vote matters, equity financing mechanics, common stock structure, business risks, and formal disclosure controls around product approvals and development programs.
ROCKET PHARMACEUTICALS, INC. (RCKT) CEO Gaurav Shah reported selling 2,293 shares of common stock on 2026-08-18 at $3.381 per share. The sale was made to pay tax withholding obligations related to vesting Restricted Stock Units (RSUs). After this transaction, he holds 1,056,594 shares directly (including RSUs), plus 207,897 shares held indirectly by his spouse and 198,341 shares held indirectly by the Gaurav D. Shah Irrevocable Trust.
ROCKET PHARMACEUTICALS, INC. (RCKT) is the issuer for which Gaurav Shah has filed a Rule 144 notice to sell restricted common stock. The notice covers a proposed sale of 2,293 shares, arising from restricted stock vesting on August 14, 2026, with prior sales disclosed over the preceding three months.
ROCKET PHARMACEUTICALS, INC. (RCKT) is the issuer for a planned resale of common stock under Rule 144 for the account of officer Martin Wilson. A notice was filed for the potential sale of 631 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $2,133.66 as of 08/18/2026 on NASDAQ. The shares derive from restricted stock vesting on 08/14/2026 and are characterized as compensation. In the prior three months, Wilson reported sales of 662 shares for $1,995.53 on 05/19/2026 and 3,493 shares for $11,810.18 on 08/13/2026. The filer notes that the sale includes shares to cover a tax obligation from the settlement of a vested equity award.
ROCKET PHARMACEUTICALS, INC. (RCKT) is the issuer for which a Form 144 notice has been filed relating to planned sales of common stock held for the account of former officer John Militello. The notice lists 1,252 shares of common stock held in an account at Fidelity Brokerage Services LLC as of 08/18/2026, with a stated market value of $4,233.51 and listing on NASDAQ.
The filing discloses that Militello received restricted stock vesting events of 887 shares on 08/11/2026 and 365 shares on 08/14/2026 as compensation from the issuer, and that 384 shares of common stock were sold on 05/19/2026 for $1,157.53 during the prior three months. A remark explains that the sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
ROCKET PHARMACEUTICALS, INC. CEO Gaurav Shah reported a sale of 2,837 shares of common stock on 2026-08-13 at $3.3810 per share. According to the company’s disclosure, these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs). After this sale, Shah held 1,058,887 shares directly, which include RSUs that convert to common stock on a one-for-one basis, plus indirect holdings of 207,897 shares through his spouse and 198,341 shares through the Gaurav D. Shah Irrevocable Trust.
ROCKET PHARMACEUTICALS, INC. executive Martin Wilson, General Counsel, reported a sale of 3,493 shares of common stock on 2026-08-13 at $3.381 per share. The sale was made to cover tax withholding obligations arising from the vesting of Restricted Stock Units, and Wilson now holds 674,484 shares directly, including RSUs that convert to common stock on a one-for-one basis.
Rocket Pharmaceuticals, Inc. Chief Operating Officer Christopher James Stevens reported selling 36,658 shares of common stock on 2026-08-11 at $3.499 per share. According to the company’s disclosure, these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs). Following this tax-related sale, Stevens directly holds 505,784 shares of common stock, including RSUs that convert to common stock on a one-for-one basis.
Rocket Pharmaceuticals, Inc. executive Sarbani Chaudhuri sold 4,701 shares of common stock on August 11, 2026, at $3.499 per share. The filing states the shares were sold to pay tax withholding obligations related to vesting RSUs. After this transaction, Chaudhuri directly held 262,809 shares, including Restricted Stock Units that convert to common stock on a one-for-one basis.
RCKT reporting person Martin Wilson filed a notice of proposed sale of common stock. The filing lists up to 3,493 common shares to be sold through Fidelity Brokerage Services LLC on or after 08/13/2026, following a restricted stock vesting event for 3,493 shares on 08/11/2026 as compensation. It also discloses prior sales of 3,361 shares for $12,118.42 on 05/13/2026 and 662 shares for $1,995.53 on 05/19/2026.
Gaurav Shah filed to sell 2,837 shares of common stock of the issuer of RCKT through Fidelity Brokerage Services LLC on August 13, 2026, listed on NASDAQ, with an indicated value of $9,592.18. The shares relate to restricted stock vesting designated as compensation.
Over the prior three months, Shah reported sales of 2,728 shares for $9,836.08 on May 13, 2026, 2,409 shares for $7,261.69 on May 19, 2026, and 55,684 shares for $171,818.55 on May 21, 2026.